Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-05-23
1996-09-24
Spivack, Phyllis G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 3133, A61K 3171
Patent
active
055591213
ABSTRACT:
The present invention comprises oral rapamycin formulations which contain, per 100 ml of the formulation, from about 0.01 to about 10.0 grams per 100 ml of rapamycin, from about 0.1 to about 10 ml of surfactant, from about 0.1 to about 25 ml of N,N-dimethylacetamide, and from about 65 to about 99.8 ml of a lecithin or phospholipid solution.
REFERENCES:
patent: 3929992 (1975-12-01), Sehgal et al.
patent: 3993749 (1976-11-01), Sehgal et al.
patent: 4885171 (1989-12-01), Surendra et al.
patent: 5080899 (1992-01-01), Sturm et al.
patent: 5100899 (1992-03-01), Caln
Physicians' Desk Reference, 45th ed., 1991, pp. 2119-2122, Medical Economics Company, Inc.
Physicians' Desk Reference, 45th ed., 1991, pp. 785-787, Medical Economics Company, Inc.
Luke et al., Effects of Cyclosporine on the Isolated Perfused Rat Kidney, Transplantation, vol. 43, No. 6, pp. 795-799, 1987.
Venkataram, et al., Pharmacokinetics of Two Alternative Dosage Forms for Cyclosporine: Liposomes and Intralipid, Journal of Pharmaceutical Sciences, vol. 79, No. 3, pp. 216-219, 1990.
Thiel, et al., Acutely Impaired Renal Function During Intravenous Administration of Cyclosporine A: A Cremaphore Side-Effect, Clinical Nephrology, vol. 25, Suppl. No. 1., pp. S40-42, 1986.
Honbo, et al., The Oral Dosage Form of FK-506, Transplanation Proceedings, vol. XIX, No. 5, Suppl. 6, pp. 17-22, 1987;.
Stepkowski, et al., Rapamycin, A Potent Immunosuppressive Drug for Vascularized Heart, Kidney, and Small Bowel Transplantation in the Rat, Transplantation, vol. 51, No. 1, pp. 22-24, 1991.
Kahan, et al., Synergistic Interactions of Cyclosporine and Rapamycin to Inhibit Immune Performances of Normal Human Peripheral Blood Lymphocytes In Vitro, Transplantation, vol. 51, No. 1, pp. 232-237, 1991.
Intl. Pharm. Abstracts--FK-506, Immunosuppressant for the 1990s, Macleod, et al., Lancet, 337, pp. 25-27, Jan. 5, 1991.
Intl. Pharm. Abstracts, FK-506: Discussion of a New Investigationsl Drug, C. G. Forde, ASHP Midyear Clinical Meeting, 25, p. 446D, Dec. 1990.
Intl. Pharm. Abstracts, FK-506, Kidney Transplantation Under FK 506, Starzl, et al., JAMA, 264, pp. 63-67, Jul. 4, 1990.
Intl. Pharm. Abstracts--FK-506 In Steroid-Resistant Focal Sclerosing Glomerulonephritis of Childhood, McCauley, et al., Lancet, 335, p. 674, Mar. 17, 1990.
Intl. Pharm. Abstracts, New Drug Could Replace Cyclosporin in Transplant Drug Therapy, Anon, Am. Pharm. NS, 30, 16, Jan. 1990.
Intl. Pharm. Abstracts, Treatment of Cyclosporin Induced Hemolytic-Uremic Syndrome with FK-506, McCauley, et al., Lancet, 2, 1516, Dec. 23-30, 1989.
Intl. Pharm. Abstracts--FK-506 for Liver, Kidney, and Pancreas Transplantation; Starzl, et al., Lancet, 2, 1000-1004, Oct. 28, 1989.
The Merck Index, Ninth Ed., pp. 5287-5288, 1976.
Harrison Maureen M.
Leonard Thomas W.
Ofslager Christian L.
Waranis Robert P.
American Home Products Corporation
Eck Steven R.
Spivack Phyllis G.
LandOfFree
Rapamycin formulations for oral administration does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Rapamycin formulations for oral administration, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Rapamycin formulations for oral administration will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1928621